×

Therapeutic Aptamer

Discovery Platform

Pipeline

AlloMAp Platform Programs

Program Indication Discovery Lead Optimization Preclinical Clinical
AST-101 T1DM/T2DM        
AST-102 T2DM        
AST-103 NASH, DM        

BiFAp Platform Programs

Program Indication Discovery Lead Optimization Preclinical Clinical
AST-201 Liver cancer        
AST-202 AMD, DR        
AST-301 GMB        
AST-302 DM        

AST-101

Allosteric agonist aptamer to insulin receptor without side effects

- Low weight gain / Reduced CVD/cancer risks
- No insulin-induced insulin resistance

AST-101

AST-101 developmental status

- Selected “ Big Pharma Joint R&D Program “ and supported by Korea Drug Development Fund(KDDF)
· Discovery (KDDF201601-04)
· Preclinical (KDDF201809-05)
- 2020 4Q : IND filing & Phase I study

AST-102

Development of the insulin sensitizer with novel MoA

- Reduced risk of insulin-induced hypoglycemia
- Effective glycemic control by improving insulin sensitivity

AST-102

AST-102 developmental status

AST-201

Unmet needs for liver cancer

- Ranks 12th on Incidence rate, ranks 4th on mortality rate
- High unmet medical needs

AST-201

- GPC3-targeted BiFAp aptamer incorporated with gemcitabine
- Anti-cancer effect specific to GPC3-expressing hepatocellular carcinoma cells

AST-201 development status

Aptamer Sciences, Inc.

Tel. +82-31-786-0317 | Fax. +82-31-786-0319 | E-mail. aptamer@aptsci.com

407 Ho, healthcare Innovation Park, 172, Dolma-ro, Bundang-gu Seongnam-si, Gyeonggi-do, Republic of Korea (13605)

TOP